Quintrio
Home

Stock overview

Eupraxia Pharmaceuticals Inc. Common Stock

EPRX

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.

Last trade $6.75
Day change -$0.59 (-8.04%)
Day range $6.71 – $7.35
Volume 1,101,787
Market cap $494M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for EPRX.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for EPRX.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences

Eupraxia Pharmaceuticals announced that three abstracts from its Phase 1b/2 RESOLVE trial of EP-104GI for treating eosinophilic esophagitis (EoE) have been accepted for presentation at the ACG 2026 Annual Scientific Meeting in Nashville (October 9-14) and UEG Week 2026 in Barcelona (October 17-20). The presentations will showcase data on improvements in dysphagia and histopathological features persisting over 52 weeks during dose escalation. Phase 2b interim data is expected in December 2026.

GlobeNewswire Inc.

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals announced positive 52-week data from its Phase 1b/2a RESOLVE trial of EP-104GI for treating eosinophilic esophagitis (EoE). The highest dose cohorts demonstrated durable symptom responses with 64% of patients maintaining clinical remission at 52 weeks, meaningful histologic improvements, and a favorable safety profile with no serious adverse events or oropharyngeal candidiasis reported. The company plans to report Phase 2b interim data in December 2026.

GlobeNewswire Inc.

Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders

Eupraxia Pharmaceuticals held its Annual General Meeting on June 18, 2026, where all seven board nominees were elected with strong shareholder support. The company also re-appointed KPMG LLP as auditor. Eupraxia is a clinical-stage biotech company developing locally delivered, extended-release products using its proprietary Diffusphere™ technology, with current programs in pain management and inflammatory gastrointestinal disease.

GlobeNewswire Inc.

Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting

Eupraxia Pharmaceuticals announced it will present 4 abstracts at Digestive Disease Week (May 2-5, 2026) showcasing clinical data from its Phase 1b/2 RESOLVE trial of EP-104GI for treating eosinophilic esophagitis. The presentations include an oral presentation on dose escalation leading to persistent histological improvements over 36 weeks, plus three poster presentations on endoscopic features, dysphagia improvements, and dose optimization. The company will also host a virtual investor event discussing esophageal strictures and EP-104GI's potential.

GlobeNewswire Inc.

Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

Eupraxia Pharmaceuticals announced positive 36-week data from the highest dose cohort (Cohort 9) of its Phase 1b/2a RESOLVE trial for EP-104GI in treating eosinophilic esophagitis. The trial showed robust tissue health improvements with 90% reduction in EoEHSS Stage and 72% reduction in Peak Eosinophil Count, along with 66% clinical remission rate in symptoms. The drug demonstrated excellent safety with no serious adverse events reported across 31 patients and over 230 patient-months of follow-up. Phase 2b placebo-controlled results are expected in Q4 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.